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Professor Lewis (Lewis, 2015) makes some strong argu-
ments and raises some important questions about routine
testing of men for DNA fragmentation (DNA-F) during a work-
up for infertility. It is indeed disappointing that data are in-
adequate to recommend routine DNA-F testing.
Sperm DNA-F has not consistently been shown to distin-
guish between couples who will or will not become preg-
nant with expectant management, intrauterine insemination
(IUI), IVF or IVF–intracytoplasmic sperm injection (ICSI). In
a large number of studies, men who achieved fertilization,
pregnancy or live birth were shown to have lower sperm DNA-F
than men who did not. These studies, however, also show that
some couples with high sperm DNA-F are able to become preg-
nant using less invasive and less costly methods within a time
frame that is reasonable for many couples. Other studies have
failed to ﬁnd a difference in outcome for men that differ in
sperm DNA-F. A lack of consensus still remains on the utility
of these tests.
Although DNA-F testing is promising as part of male infer-
tility diagnosis, we do not have sufﬁcient evidence of its pre-
dictive value to recommend universal adoption of this
methodology, largely owing to the small, heterogeneous popu-
lations, variations in methodology and inadequate experi-
mental designs of existing studies (Zini, 2014). If studies are
underpowered, have defects in design and are heteroge-
neous, it is not evidence-based medicine to recommend ap-
plication of the results to the entire patient population. The
editorial (Drobnis and Johnson, 2015) did not suggest that the
European Society of Human Reproduction and Embryology
(ESHRE) position report (Barratt et al., 2010) opposed DNA-F
testing; rather that the ESHRE report, along with the Ameri-
can Society for reproductive Medicine Practice Committee
guidelines (ASRMPractice Committee, 2013), recommend that
more research is needed. The widespread use of ICSI before
its safetywas evaluated in experimental species is not a shining
moment in reproductive medicine (de Wert, 1998); indeed,
clinical trials in humans, before animal experiments, violates
the Nuremberg Code and the Declaration of Helsinki. We are
very fortunate that ICSI did not have adverse outcomes analo-
gous to those with Thalidomide several decades earlier.
Even with its problems of accuracy and precision, semen
analysis has an important place in diagnosis of male factor
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infertility; it is inexpensive and can suggest treatment or
further testing of the infertile man. It is exactly the deter-
mination of a man’s fertility by natural conception that is rel-
evant when beginning the work-up of an infertile couple. In
general, a man producing two or more abnormal semen analy-
ses, at an appropriate interval, should be evaluated by a prac-
titioner trained in male infertility (ASRM Practice Committee,
2015). An abnormal seman analysis can be a symptom of life-
threatening conditions, some emergent, including extreme
high blood pressure, testicular cancer and brain tumour
(Esteves et al., 2011; Jarow, 1994; Jequier, 2006). The man
should receive evaluation and treatment for his infertility
before considering medical interventions to achieve a preg-
nancy. Because it adds independent information to the semen
analysis, DNA-F testing is likely to be helpful in determining
the best treatment, if healthy lifestyle changes or medical
therapy do not allow the patient to achieve a pregnancy on
his own. It should be remembered, however, that this testing
is expensive and, in most of the world, the cost is borne by
the patient.
The possibility that ICSI improves pregnancy outcome over
IVF alone in cases with high DNA-F, is exciting, and Profes-
sor Lewis’ theories on the mechanisms for this are intrigu-
ing. High pregnancy and live birth outcomes are achieved by
ICSI. If the goal in treating infertile couples were to achieve
a pregnancy as rapidly as possible, then all patients, should
begin by using IVF–ICSI. However, assisted reproducutive tech-
niques are costly, invasive, potentially involve adverse out-
comes, and are generally reserved for cases for which other
treatment have a low chance of success (ASRM Practice
Committee, 2012; Carrell et al., 2015). Sperm DNA-F testing
may be the test we need to identify couples requiring as-
sisted reproductive techniques, donor insemination or
adoption.
In addition to information gained by the fertility work-up
of the man and woman, other social and ﬁnancial concerns
may affect the couple’s decision on which fertility treat-
ment is best for them. An important consideration for
worldwide reproductive health is that assisted reproductive
technique treatments are inaccessible for many infertile
couples. In the USA, medical insurance does not cover
assisted reproductive techniques in most states, and
one cycle of IVF costs about 20% of the median household
income (US$52,000 per year in 2013). Worldwide, many in-
fertile couples currently beneﬁt from the less expensive
and less invasive treatment of intrauterine insemination,
even though the per-cycle pregnancy rate is relatively low,
and not all patients will achieve success (Ombelet et al.,
2014).
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